MDGA2 is a novel tumour suppressor cooperating with DMAP1 in gastric cancer and is associated with disease outcome

BACKGROUND: Using the promoter methylation assay, we have shown that MDGA2 (MAM domain containing glycosylphosphatidylinositol anchor 2) is preferentially methylated in gastric cancer. We analysed its biological effects and prognostic significance in gastric cancer. METHODS: MDGA2 methylation status...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Gut
Main Authors: Wang, Kunning, Liang, Qiaoyi, Li, Xiaoxing, Tsoi, Ho, Zhang, Jingwan, Wang, Hua, Go, Minnie Y Y, Chiu, Philip W Y, Ng, Enders K W, Sung, Joseph J Y, Yu, Jun
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2016
Assuntos:
Stomach
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5036270/
https://ncbi.nlm.nih.gov/pubmed/26206665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gutjnl-2015-309276
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados